TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$150.98 USD
-8.40 (-5.27%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $152.00 +1.02 (0.68%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
TransMedics (TMDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$179.44 | $208.00 | $153.00 | 12.59% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for TransMedics comes to $179.44. The forecasts range from a low of $153.00 to a high of $208.00. The average price target represents an increase of 12.59% from the last closing price of $159.38.
Analyst Price Targets (9 )
Broker Rating
TransMedics currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 70% and 20% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 2 | 2 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/21/2024 | Needham & Company | Michael Matson | Not Available | Moderate Buy |
8/1/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/31/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
7/31/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
6/6/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
6/4/2024 | Stephens | George Sellers | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 10 |
Average Target Price | $179.44 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 78 of 253 |
Current Quarter EPS Est: | 0.27 |